Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 12, 2015, Pages 3782-3787

  Roy, Chad J ^a,b   Brey, Robert N ^c,h   Mantis, Nicholas J ^d,e   Mapes, Kelly ^f   Pop, Iliodora V ^f   Pop, Laurentiu M ^f   Ruback, Stephen ^f   Killeen, Stephanie Z ^b   Doyle Meyers, Lara ^b   Vinet Oliphant, Heather S ^b   Didier, Peter J ^b   Vitetta, Ellen S ^f,g  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c Soligenix Inc   (United States)

^d WADSWORTH CENTER   (United States)

^e UNIVERSITY AT ALBANY   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h Kinesis Vaccines ^*  (United States)

Author keywords

Immunoprofiling; Monoclonal antibody; Rhesus macaques; Ricin; Vaccine

Indexed keywords

ALUMINUM; ANTITOXIN; EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RICIN; RICIN ANTIBODY; RICIN VACCINE; UNCLASSIFIED DRUG; AEROSOL; IMMUNOGLOBULIN G; RIVAX; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ESCHERICHIA COLI; HUMAN; IMMUNOGENICITY; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RHESUS MONKEY; THERMOSTABILITY; AEROSOL; ANIMAL; CHEMISTRY; CONFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; LUNG; PATHOLOGY; TEMPERATURE;

ANIMALIA; ESCHERICHIA COLI; MACACA MULATTA; MAMMALIA; MUS; ORYCTOLAGUS CUNICULUS; RICINUS COMMUNIS;

AEROSOLS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; EPITOPES; HUMANS; IMMUNOGLOBULIN G; LUNG; MACACA MULATTA; MICE; MOLECULAR CONFORMATION; RICIN; TEMPERATURE; VACCINES;

EID: 84925428438     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1502585112     Document Type: Article

References (31)

1. Franz DR, Jaax NK (1997) Ricin toxin. Textbook of Military Medicine, eds Sidell FR, Takafuji ET, Franz DR (Office of the Surgeon General, Department of the Army, Washington, DC), pp 631-642.
2. Endo Y, Mitsui K, Motizuki M, Tsurugi K (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 262(12):5908-5912.
3. Endo Y, Tsurugi K (1987) RNA N-glycosidase activity of ricin A-chain.Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J Biol Chem 262(17):8128-8130.
4. Montfort W, et al. (1987) The three-dimensional structure of ricin at 2.8 A. J Biol Chem 262(11):5398-5403.
5. Bhaskaran M, et al. (2014) Pathology of lethal and sublethal doses of aerosolized ricin in rhesus macaques. Toxicol Pathol 42(3):573-581.
6. Carra JH, et al. (2007) Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. Vaccine 25(21):4149-4158.
7. McLain DE, et al. (2012) Protective effect of two recombinant ricin subunit vaccines in the New Zealand white rabbit subjected to a lethal aerosolized ricin challenge: Survival, immunological response, and histopathological findings. Toxicol Sci 126(1):72-83.
8. Smallshaw JE, et al. (2002) A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 20(27-28):3422-3427.
9. Smallshaw JE, Richardson JA, Pincus S, Schindler J, Vitetta ES (2005) Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine 23(39):4775-4784.
10. Vitetta ES, et al. (2006) A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci USA 103(7):2268-2273.
11. Vitetta ES, Smallshaw JE, Schindler J (2012) Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine. Clin Vaccine Immunol 19(10):1697-1699.
12. Smallshaw JE, et al. (2003) Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol 21(4):387-391.
13. Legler PM, Brey RN, Smallshaw JE, Vitetta ES, Millard CB (2011) Structure of RiVax: A recombinant ricin vaccine. Acta Crystallogr D Biol Crystallogr 67(Pt 9):826-830.
14. Smallshaw JE, Richardson JA, Vitetta ES (2007) RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 25(42):7459-7469.
15. McLain DE, Horn TL, Detrisac CJ, Lindsey CY, Smith LA (2011) Progress in biological threat agent vaccine development: A repeat-dose toxicity study of a recombinant ricin toxin A-chain (rRTA) 1-33/44-198 vaccine (RVEc) in male and female New Zealand white rabbits. Int J Toxicol 30(2):143-152.
16. Porter A, et al. (2011) Evaluation of a ricin vaccine candidate (RVEc) for human toxicity using an in vitro vascular leak assay. Toxicon 58(1):68-75.
17. Plotkin SA (2008) Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis 47(3):401-409.
18. Plotkin SA (2013) Complex correlates of protection after vaccination. Clin Infect Dis 56(10):1458-1465.
19. O'Hara JM, Kasten-Jolly JC, Reynolds CE, Mantis NJ (2014) Localization of non-linear neutralizing B cell epitopes on ricin toxin's enzymatic subunit (RTA). Immunol Lett 158(1-2):7-13.
20. O' Hara JM, et al. (2010) Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine 28(43):7035-7046.
21. Hassett KJ, et al. (2013) Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization. Eur J Pharm Biopharm 85(2):279-286.
22. Peek LJ, Brey RN, Middaugh CR (2007) A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. J Pharm Sci 96(1):44-60.
23. Roy CJ, et al. (2014) Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis 209(12):1891-1899.
24. FDA (2014) Guidance for Industry: Product Development Under the Animal Rule. Available at www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf. Accessed January 15, 2015.
25. Smallshaw JE, Vitetta ES (2010) A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity. Vaccine 28(12):2428-2435.
26. Smallshaw JE, Vitetta ES (2012) Ricin vaccine development. Curr Top Microbiol Immunol 357:259-272.
27. Sully EK, et al. (2014) Chimeric plantibody passively protects mice against aerosolized ricin challenge. Clin Vaccine Immunol 21(5):777-782.
28. Roy CJ, Song K, Sivasubramani SK, Gardner DJ, Pincus SH (2012) Animal models of ricin toxicosis. Curr Top Microbiol Immunol 357:243-257.
29. Meng R, et al. (2004) The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin Cancer Res 10(4):1274-1281.
30. Spiridon CI, Guinn S, Vitetta ES (2004) A comparison of the in vitro and in vivo activities of IgG and F(ab?)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res 10(10):3542-3551.
31. McGuinness CR, Mantis NJ (2006) Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit. Infect Immun 74(6):3463-3470.